Literature DB >> 15585407

Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses.

Hoyin Mok1, Donna J Palmer, Philip Ng, Michael A Barry.   

Abstract

Adenoviruses are robust gene delivery vectors in vivo, but are limited by their propensity to provoke strong innate and adaptive responses. Previous work has demonstrated that polyethylene glycol (PEG) modification of adenovirus can protect the vectors from preexisting and adaptive immune responses by reducing protein-protein interactions. To test whether PEGylation can reduce innate immune responses to adenovirus by reducing their interactions with immune cells, first-generation (FG-Ad) and helper-dependent (HD-Ad) Ad5 vectors were PEGylated with SPA-PEG and tested in vitro and in vivo. We demonstrate that increasing PEGylation ablated in vitro transduction, but surprisingly had no negative effect on the level or distribution of in vivo gene delivery. This poor in vitro transduction could be rescued in part by physically forcing the PEGylated vectors onto cells, suggesting that physiological forces in vivo may enable transduction via heparin sulfate proteoglycan and integrin interactions. While transduction remained the same as for unmodified vectors, the PEGylated vectors reduced innate IL-6 responses by 70 and 50% in vivo for FG-Ad and HD-Ad. These reduced innate responses paralleled similar reductions in vector uptake by macrophages in vitro and Kupffer cells in vivo. These data suggest that PEGylation of Ad vectors can reduce innate immune responses without reducing transduction in vivo. These data also suggest that nonspecific vector uptake by macrophages and Kupffer cells may be critically involved in the initial activation of innate immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15585407     DOI: 10.1016/j.ymthe.2004.09.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  83 in total

Review 1.  Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials.

Authors:  Jaesung Kim; Pyung-Hwan Kim; Sung Wan Kim; Chae-Ok Yun
Journal:  Biomaterials       Date:  2011-12-03       Impact factor: 12.479

2.  Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.

Authors:  Cédric Sapet; Christophe Pellegrino; Nicolas Laurent; Flavie Sicard; Olivier Zelphati
Journal:  Pharm Res       Date:  2011-12-07       Impact factor: 4.200

3.  Imaging luciferase-expressing viruses.

Authors:  Michael A Barry; Shannon May; Eric A Weaver
Journal:  Methods Mol Biol       Date:  2012

Review 4.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

5.  Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene.

Authors:  Zhengming Xiong; Zhen Cheng; Xianzhong Zhang; Manish Patel; Joseph C Wu; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

Review 6.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

7.  Structure-based identification of a major neutralizing site in an adenovirus hexon.

Authors:  Susan L Pichla-Gollon; Mark Drinker; Xiangyang Zhou; Feng Xue; John J Rux; Guang-Ping Gao; James M Wilson; Hildegund C J Ertl; Roger M Burnett; Jeffrey M Bergelson
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

8.  Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration.

Authors:  Xi Zhan; Kenny K Tran; Hong Shen
Journal:  Mol Pharm       Date:  2012-11-20       Impact factor: 4.939

Review 9.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

10.  Stealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X.

Authors:  Karin L Lee; Sourabh Shukla; Mengzhi Wu; Nadia R Ayat; Caroline E El Sanadi; Amy M Wen; John F Edelbrock; Jonathan K Pokorski; Ulrich Commandeur; George R Dubyak; Nicole F Steinmetz
Journal:  Acta Biomater       Date:  2015-03-10       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.